Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Streptokinase is dispensable in Streptococcus dysgalactiae subspecies equisimilis infections of human dendritic cells.
Sci Rep
January 2025
Department of Molecular Genetics and Infection Biology, University of Greifswald, 17489, Greifswald, Germany.
In recent years, increased numbers of severe Streptococcus dysgalactiae subsp. equisimilis (SDSE) infections, including necrotizing soft tissue infections (NSTIs), have been reported. One of the main virulence factors of SDSE is streptokinase (Ska).
View Article and Find Full Text PDFGroup a remains viable inside fibrin clots and gains access to human plasminogen for subsequent fibrinolysis and dissemination.
Microbiol Spectr
January 2025
Department of Biological Sciences, University of Notre Dame, Notre Dame, Indiana, USA.
Unlabelled: Group A (GAS) is a major human pathogen that causes several invasive diseases including necrotizing fasciitis. The host coagulation cascade initiates fibrin clots to sequester bacteria to prevent dissemination into deeper tissues. GAS, especially skin-tropic bacterial strains, utilize specific virulence factors, plasminogen binding M-protein (PAM) and streptokinase (SK), to manipulate hemostasis and activate plasminogen to cause fibrinolysis and fibrin clot escape.
View Article and Find Full Text PDFExploring Peripheral and Cardiac Immune Responses in a Pneumosepsis Mouse Model with Group A Streptococcus.
Am J Respir Cell Mol Biol
January 2025
Rostock University Medical Center, Institute of Medical Microbiology, Virology and Hygiene, Rostock, Germany.
(Group A Streptococcus, GAS) is a human pathogen that causes local and systemic infections of the skin and mucous membranes. However, GAS is also found asymptomatically in the nasopharynx of infants. GAS infections, including pharyngitis and invasive pneumosepsis, pose significant public health concerns.
View Article and Find Full Text PDFAssociation between Free Tri-iodothyronine Level and In-Hospital Outcome in Patients with Acute ST-Elevation Myocardial Infarction Treated with Streptokinase Therapy.
Mymensingh Med J
January 2025
Dr SM Nazmul Huda, Assistant Registrar, Department of Cardiology, National Institute of Cardiovascular Diseases (NICVD), Dhaka, Bangladesh; E-mail:
Low free Tri-iodothyronine (FT₃) levels are generally associated with poor prognosis in patients with various critical illnesses. Acute ST-segment Elevation Myocardial Infarction (STEMI) represents the most lethal form of Acute Coronary Syndrome (ACS) with substantial short- and long-term mortality. This study was done to assess the association between FT₃ levels and in-hospital outcome of the STEMI patients treated with streptokinase therapy.
View Article and Find Full Text PDFSix Versus Three Doses of Intrapleural Streptokinase in Childhood Empyema: A Randomized Controlled Trial.
Pediatr Pulmonol
January 2025
Department of Pediatric Surgery, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Objective: To compare the efficacy and safety of administering six doses of intrapleural streptokinase (SK) versus the conventional three doses, in children with empyema.
Study Design: In this open label, placebo-controlled, randomized trial, we enrolled 53 children with empyema, who received three doses of intrapleural SK. Thereafter, those without clinical improvement (n = 34) and those showing clinical improvement but having persistent pleural fluid width > 10 mm on chest ultrasonography (n = 13), were randomized to receive three additional doses of SK, or three doses of placebo (normal saline).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!